albuterol has been researched along with Cardiac Failure in 50 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The influence of two cardiac inotropic drugs, dobutamine and salbutamol, on plasma atrial natriuretic factor (ANF) was investigated in 20 patients with congestive heart failure." | 7.68 | Effects of dobutamine and salbutamol on haemodynamics and atrial natriuretic factor in patients with severe congestive heart failure. ( Keller, N; Larsen, J; Sykulski, R, 1991) |
| "To examine possible augmentation of the effects of isosorbide dinitrate by salbutamol, haemodynamic measurements were made in 10 patients with severe chronic congestive cardiac failure who received isosorbide dinitrate 2." | 7.66 | Haemodynamic effects of oral salbutamol alone and in combination with sublingual isosorbide dinitrate in patients with severe congestive cardiac failure. ( Banim, SO; Spurrell, RA; Stephens, JD, 1980) |
| "This study was designed to investigate and compare the haemodynamic and metabolic responses to pirbuterol and salbutamol in patients with congestive heart failure and coronary artery disease." | 5.05 | Potential value of oral beta 2-adrenoceptor agonists in congestive heart failure: a haemodynamic and metabolic study. ( Bergman, G; Jewitt, DE; Monaghan, MJ; Timmis, AD; Walker, L, 1984) |
| "Clenbuterol, a compound classified as a beta2-adrenoceptor (AR) agonist, has been employed in combination with left ventricular assist devices (LVADs) to treat patients with severe heart failure." | 3.74 | Effects of clenbuterol on contractility and Ca2+ homeostasis of isolated rat ventricular myocytes. ( Arora, M; Harding, SE; Kolettis, T; Lee, J; Siedlecka, U; Soppa, GK; Stagg, MA; Terracciano, CM; Yacoub, MH, 2008) |
| "The influence of two cardiac inotropic drugs, dobutamine and salbutamol, on plasma atrial natriuretic factor (ANF) was investigated in 20 patients with congestive heart failure." | 3.68 | Effects of dobutamine and salbutamol on haemodynamics and atrial natriuretic factor in patients with severe congestive heart failure. ( Keller, N; Larsen, J; Sykulski, R, 1991) |
| "To examine possible augmentation of the effects of isosorbide dinitrate by salbutamol, haemodynamic measurements were made in 10 patients with severe chronic congestive cardiac failure who received isosorbide dinitrate 2." | 3.66 | Haemodynamic effects of oral salbutamol alone and in combination with sublingual isosorbide dinitrate in patients with severe congestive cardiac failure. ( Banim, SO; Spurrell, RA; Stephens, JD, 1980) |
| "Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are closely related in clinical practice." | 3.01 | Potential Mechanisms Between HF and COPD: New Insights From Bioinformatics. ( Li, Z; Liu, Y; Ma, X; Sun, Z; Wang, A; Zhang, D, 2023) |
| " The first step in outpatient management should be to increase the dosage of inhaled short-acting bronchodilators." | 2.46 | Management of COPD exacerbations. ( Evensen, AE, 2010) |
| "Although large surveys have documented the favourable safety profile of beta(2)-adrenoceptor agonists (beta(2)-agonists) and, above all, that of the long-acting agents, the presence in the literature of reports of adverse cardiovascular events in patients with obstructive airway disease must induce physicians to consider this eventuality." | 2.43 | Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. ( Cazzola, M; Donner, CF; Matera, MG, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (38.00) | 18.7374 |
| 1990's | 7 (14.00) | 18.2507 |
| 2000's | 13 (26.00) | 29.6817 |
| 2010's | 9 (18.00) | 24.3611 |
| 2020's | 2 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xing, G | 1 |
| Woo, AY | 1 |
| Pan, L | 1 |
| Lin, B | 1 |
| Cheng, MS | 1 |
| Wang, A | 2 |
| Li, Z | 2 |
| Sun, Z | 2 |
| Liu, Y | 2 |
| Zhang, D | 2 |
| Ma, X | 2 |
| Tomlin, AM | 1 |
| Woods, DJ | 1 |
| Lloyd, HS | 1 |
| Stewart, RAH | 1 |
| Tilyard, MW | 1 |
| Reddy, YNV | 1 |
| Obokata, M | 1 |
| Koepp, KE | 1 |
| Egbe, AC | 1 |
| Wiley, B | 1 |
| Borlaug, BA | 1 |
| Cimato, TR | 1 |
| Canty, JM | 1 |
| Kaplan, A | 1 |
| Gruffydd-Jones, K | 1 |
| van Gemert, F | 1 |
| Kirenga, BJ | 1 |
| Medford, AR | 1 |
| Rinaldi, B | 1 |
| Capuano, A | 1 |
| Gritti, G | 1 |
| Donniacuo, M | 1 |
| Scotto Di Vettimo, A | 1 |
| Sodano, L | 1 |
| Rafaniello, C | 1 |
| Rossi, F | 1 |
| Matera, MG | 2 |
| Wang, Y | 1 |
| Yuan, J | 1 |
| Qian, Z | 1 |
| Zhang, X | 1 |
| Chen, Y | 1 |
| Hou, X | 1 |
| Zou, J | 1 |
| Chase, SC | 2 |
| Wheatley, CM | 2 |
| Olson, LJ | 2 |
| Beck, KC | 1 |
| Wentz, RJ | 1 |
| Snyder, EM | 2 |
| Taylor, BJ | 2 |
| Johnson, BD | 2 |
| Richert, ML | 1 |
| Gupta, P | 2 |
| Aggarwal, A | 1 |
| Sharma, KK | 1 |
| Paul, B | 1 |
| Hewitson, CL | 1 |
| Woodman, RJ | 1 |
| Mangoni, AA | 1 |
| Siedlecka, U | 1 |
| Arora, M | 1 |
| Kolettis, T | 1 |
| Soppa, GK | 1 |
| Lee, J | 1 |
| Stagg, MA | 1 |
| Harding, SE | 1 |
| Yacoub, MH | 1 |
| Terracciano, CM | 1 |
| Evensen, AE | 1 |
| Witte, KK | 1 |
| Morice, A | 1 |
| Cleland, JG | 1 |
| Clark, AL | 1 |
| Cazzola, M | 1 |
| Donner, CF | 1 |
| He, JQ | 1 |
| Balijepalli, RC | 1 |
| Haworth, RA | 1 |
| Kamp, TJ | 1 |
| Indik, JH | 1 |
| Osadchii, OE | 1 |
| Norton, GR | 1 |
| McKechnie, R | 1 |
| Deftereos, D | 1 |
| Woodiwiss, AJ | 1 |
| Deriaz-Chessex, S | 1 |
| Carron, P | 1 |
| Gachoud, D | 1 |
| Fournier, Y | 1 |
| Donzé, J | 1 |
| Monti, M | 1 |
| Achtari Jeanneret, L | 1 |
| Rossier, A | 1 |
| Moix, PA | 1 |
| Barras-Moret, AC | 1 |
| Wilson, P | 1 |
| Milliez, J | 1 |
| Blot, P | 1 |
| Sureau, C | 1 |
| Bijak, A | 1 |
| Czołpiński, T | 1 |
| Canepa-Anson, R | 2 |
| Dawson, JR | 3 |
| Frankl, WS | 1 |
| Kuan, P | 2 |
| Sutton, GC | 3 |
| Reuben, S | 2 |
| Poole-Wilson, PA | 3 |
| Bayliss, J | 1 |
| Norell, MS | 1 |
| Ochs, HR | 1 |
| Bodem, G | 1 |
| Blakeley, C | 1 |
| Tinker, J | 1 |
| Timmis, AD | 4 |
| Bergman, G | 1 |
| Walker, L | 1 |
| Monaghan, MJ | 1 |
| Jewitt, DE | 1 |
| Mifune, J | 1 |
| Kuramoto, K | 1 |
| Ueda, K | 1 |
| Matsushita, S | 1 |
| Kuwajima, I | 1 |
| Sakai, M | 1 |
| Iwasaki, T | 1 |
| Moroki, N | 1 |
| Murakami, M | 1 |
| Bourdillon, PD | 1 |
| Foale, RA | 1 |
| Stephens, JD | 1 |
| Banim, SO | 1 |
| Spurrell, RA | 1 |
| Fowler, MB | 1 |
| Chamberlain, DA | 2 |
| Whitehead, MI | 1 |
| Mander, AM | 1 |
| Hertogs, K | 1 |
| Williams, RM | 1 |
| Pettingale, KW | 1 |
| Gourdiole, P | 1 |
| Pequegnot, C | 1 |
| Douge, C | 1 |
| Barale, F | 1 |
| Uren, NG | 1 |
| Davies, SW | 1 |
| Jordan, SL | 1 |
| Lipkin, DP | 1 |
| Mulder, P | 1 |
| Compagnon, P | 1 |
| Devaux, B | 1 |
| Richard, V | 1 |
| Henry, JP | 1 |
| Elfertak, L | 1 |
| Wimart, MC | 1 |
| Thibout, E | 1 |
| Comoy, E | 1 |
| Macé, B | 1 |
| Thuillez, C | 1 |
| Jenne, JW | 1 |
| Lindmark, B | 1 |
| Ottosson, A | 1 |
| Crilley, JG | 1 |
| Dark, JH | 1 |
| Hall, JA | 1 |
| Harrington, D | 1 |
| Chua, TP | 1 |
| Coats, AJ | 1 |
| Desai, MY | 1 |
| De la Peña-Almaguer, E | 1 |
| Mannting, F | 1 |
| Peng, Y | 1 |
| Ma, S | 1 |
| Zhang, S | 1 |
| Li, Y | 1 |
| Yang, L | 1 |
| Bian, S | 1 |
| Ng, TM | 1 |
| Munger, MA | 1 |
| Lombardi, WL | 1 |
| Doing, TH | 1 |
| Ryujin, DT | 1 |
| Young, DC | 1 |
| Lugo, RA | 1 |
| Baumann, HR | 1 |
| Strak, SK | 1 |
| Sharma, B | 1 |
| Goodwin, JF | 1 |
| Keller, N | 1 |
| Sykulski, R | 1 |
| Larsen, J | 1 |
| Cabanes, LR | 1 |
| Weber, SN | 1 |
| Matran, R | 1 |
| Regnard, J | 1 |
| Richard, MO | 1 |
| Degeorges, ME | 1 |
| Lockhart, A | 1 |
| Tan, SL | 1 |
| Lui, PS | 1 |
| Salmon, YM | 1 |
| Mettauer, B | 1 |
| Rouleau, JL | 1 |
| Burgess, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial[NCT02885636] | Phase 3 | 30 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The exercise PVR at 20 Watts after study drug relative to the exercise PVR at 20 Watts in the initial assessment prior to study drug. This measurement is made by subtracting pulmonary capillary wedge pressure from the mean pulmonary arterial pressure and dividing by cardiac output in liters per minute and reported as wood units. A decrease in PVR measured by wood units would be considered a favorable response. (NCT02885636)
Timeframe: Baseline, 10 minutes after intervention during exercise
| Intervention | wood units (Mean) |
|---|---|
| Inhaled Albuterol | -0.6 |
| Inhaled Saline Placebo | 0.1 |
Cardiac output was calculated using the direct Fick method of breath-by-breath oxygen consumption (V02)/arterial-venous oxygen content difference (AVO2 diff). (NCT02885636)
Timeframe: Baseline, 10 minutes after intervention during exercise
| Intervention | L/min (Mean) |
|---|---|
| Inhaled Albuterol | 2.0 |
| Inhaled Saline Placebo | 0.1 |
Pulmonary artery compliance was calculated as the ratio of stroke volume/pulmonary artery pulse pressure. (NCT02885636)
Timeframe: Baseline, 10 minutes after intervention during exercise
| Intervention | mL/mm Hg (Mean) |
|---|---|
| Inhaled Albuterol | 1.6 |
| Inhaled Saline Placebo | 0.0 |
Pulmonary artery pressure was measured using a high-fidelity micromanometer advanced through the lumen of a fluid-filled catheter. (NCT02885636)
Timeframe: Baseline, 10 minutes after intervention during exercise
| Intervention | mm Hg (Mean) |
|---|---|
| Inhaled Albuterol | -8 |
| Inhaled Saline Placebo | -2 |
Pulmonary capillary wedge pressure was measured using a high-fidelity micromanometer advanced through the lumen of a fluid-filled catheter. PCWP position was confirmed by appearance on fluoroscopy, characteristic pressure waveforms, and oximetry. (NCT02885636)
Timeframe: Baseline, 10 minutes after intervention during exercise
| Intervention | mm Hg (Mean) |
|---|---|
| Inhaled Albuterol | -2 |
| Inhaled Saline Placebo | -3 |
Pulmonary elastance was calculated by the ratio of pulmonary artery systolic pressure/stroke volume. (NCT02885636)
Timeframe: Baseline, 10 minutes after intervention during exercise
| Intervention | mm Hg/mL (Mean) |
|---|---|
| Inhaled Albuterol | -0.17 |
| Inhaled Saline Placebo | -0.05 |
RA was measured using a high-fidelity micromanometer advanced through the lumen of a fluid-filled catheter. (NCT02885636)
Timeframe: Baseline, 10 minutes after intervention during exercise
| Intervention | mm Hg (Mean) |
|---|---|
| Inhaled Albuterol | -5 |
| Inhaled Saline Placebo | -1 |
Cardiac output was calculated using the direct Fick method of breath-by-breath oxygen consumption (V02)/arterial-venous oxygen content difference (AVO2 diff). (NCT02885636)
Timeframe: Baseline, 10 minutes after intervention
| Intervention | L/min (Mean) |
|---|---|
| Inhaled Albuterol | 0.6 |
| Inhaled Saline Placebo | 0.4 |
Pulmonary artery compliance was calculated as the ratio of stroke volume/pulmonary artery pulse pressure. (NCT02885636)
Timeframe: Baseline, 10 minutes after intervention
| Intervention | mL/mm Hg (Mean) |
|---|---|
| Inhaled Albuterol | 1.2 |
| Inhaled Saline Placebo | 0.7 |
Pulmonary artery pressure was measured using a high-fidelity micromanometer advanced through the lumen of a fluid-filled catheter. (NCT02885636)
Timeframe: Baseline, 10 minutes after intervention
| Intervention | mm Hg (Mean) |
|---|---|
| Inhaled Albuterol | -5 |
| Inhaled Saline Placebo | -3 |
Pulmonary capillary wedge pressure was measured using a high-fidelity micromanometer advanced through the lumen of a fluid-filled catheter. PCWP position was confirmed by appearance on fluoroscopy, characteristic pressure waveforms, and oximetry. (NCT02885636)
Timeframe: Baseline, 10 minutes after intervention
| Intervention | mm Hg (Mean) |
|---|---|
| Inhaled Albuterol | -2 |
| Inhaled Saline Placebo | -2 |
Pulmonary elastance was calculated by the ratio of pulmonary artery systolic pressure/stroke volume. (NCT02885636)
Timeframe: Baseline, 10 minutes after intervention
| Intervention | mm Hg/mL (Mean) |
|---|---|
| Inhaled Albuterol | -0.11 |
| Inhaled Saline Placebo | -0.03 |
The resting PVR after study drug relative to the resting PVR in the initial assessment prior to study drug. This measurement is made by subtracting pulmonary capillary wedge pressure from the mean pulmonary arterial pressure and dividing by cardiac output in liters per minute and reported as wood units. (NCT02885636)
Timeframe: Baseline, 10 minutes after intervention
| Intervention | wood units (Mean) |
|---|---|
| Inhaled Albuterol | -0.6 |
| Inhaled Saline Placebo | -0.3 |
RA was measured using a high-fidelity micromanometer advanced through the lumen of a fluid-filled catheter. (NCT02885636)
Timeframe: Baseline, 10 minutes after intervention
| Intervention | mm Hg (Mean) |
|---|---|
| Inhaled Albuterol | -3 |
| Inhaled Saline Placebo | -1 |
7 reviews available for albuterol and Cardiac Failure
| Article | Year |
|---|---|
Recent Advances in β
Topics: Adrenergic beta-2 Receptor Agonists; Asthma; Clinical Trials as Topic; Heart Failure; Humans; Muscle | 2020 |
Potential Mechanisms Between HF and COPD: New Insights From Bioinformatics.
Topics: Albuterol; Computational Biology; Heart Failure; Humans; MicroRNAs; Pulmonary Disease, Chronic Obstr | 2023 |
Potential Mechanisms Between HF and COPD: New Insights From Bioinformatics.
Topics: Albuterol; Computational Biology; Heart Failure; Humans; MicroRNAs; Pulmonary Disease, Chronic Obstr | 2023 |
Potential Mechanisms Between HF and COPD: New Insights From Bioinformatics.
Topics: Albuterol; Computational Biology; Heart Failure; Humans; MicroRNAs; Pulmonary Disease, Chronic Obstr | 2023 |
Potential Mechanisms Between HF and COPD: New Insights From Bioinformatics.
Topics: Albuterol; Computational Biology; Heart Failure; Humans; MicroRNAs; Pulmonary Disease, Chronic Obstr | 2023 |
Management of COPD exacerbations.
Topics: Albuterol; Anti-Bacterial Agents; Bronchodilator Agents; Comorbidity; Disease Progression; Glucocort | 2010 |
Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol | 2005 |
[New drugs with positive inotropic action].
Topics: Adrenergic beta-Agonists; Albuterol; Aminopyridines; Amrinone; Cardiotonic Agents; Chronic Disease; | 1982 |
Beta 2 adrenoceptor agonists. Pharmacology, metabolic effects and arrhythmias.
Topics: Adrenergic beta-Agonists; Albuterol; Arrhythmias, Cardiac; Blood Glucose; Epinephrine; Ethanolamines | 1982 |
Vasodilators in acute circulatory failure.
Topics: Albuterol; Captopril; Chlorpromazine; Heart Failure; Humans; Isosorbide Dinitrate; Nitroglycerin; Ni | 1983 |
8 trials available for albuterol and Cardiac Failure
| Article | Year |
|---|---|
The β-Adrenergic Agonist Albuterol Improves Pulmonary Vascular Reserve in Heart Failure With Preserved Ejection Fraction.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Albuterol; | 2019 |
Oral salbutamol for symptomatic relief in mild bronchiolitis a double blind randomized placebo controlled trial.
Topics: Acute Disease; Administration, Oral; Albuterol; Bronchiolitis; Bronchodilator Agents; Child; Double- | 2008 |
The reversibility of increased airways resistance in chronic heart failure measured by impulse oscillometry.
Topics: Aged; Airway Resistance; Albuterol; Bronchodilator Agents; Case-Control Studies; Double-Blind Method | 2004 |
Potential value of oral beta 2-adrenoceptor agonists in congestive heart failure: a haemodynamic and metabolic study.
Topics: Adult; Aged; Albuterol; Blood Glucose; Ethanolamines; Fatty Acids, Nonesterified; Female; Heart Fail | 1984 |
Hemodynamic effects of salbutamol, an oral long-acting beta-stimulant, in patients with congestive heart failure.
Topics: Administration, Oral; Aged; Albuterol; Blood Pressure; Cardiac Output; Clinical Trials as Topic; Fem | 1982 |
Inhaled bronchodilators increase maximum oxygen consumption in chronic left ventricular failure.
Topics: Administration, Inhalation; Adult; Airway Resistance; Albuterol; Bronchoconstriction; Bronchodilator | 1993 |
The effect of salbutamol on skeletal muscle in chronic heart failure.
Topics: Albuterol; Bronchodilator Agents; Double-Blind Method; Exercise Tolerance; Female; Heart Failure; Hu | 2000 |
Chronically inhaled salmeterol improves pulmonary function in heart failure.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Albuterol; Cross-Over Studies; Double-Blind Met | 2002 |
35 other studies available for albuterol and Cardiac Failure
| Article | Year |
|---|---|
Understanding medicines with a propensity to increase the risk of heart failure: Combining existing knowledge with targeted population assessment.
Topics: Aged; Aged, 80 and over; Albuterol; Antifungal Agents; Case-Control Studies; Clozapine; Diltiazem; D | 2018 |
Right Ventricular Pulmonary Coupling as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction.
Topics: Adrenergic beta-Agonists; Albuterol; Heart Failure; Heart Ventricles; Humans; Stroke Volume | 2019 |
A woman with breathlessness: a practical approach to diagnosis and management.
Topics: Albuterol; Bronchodilator Agents; Diagnosis, Differential; Disease Progression; Dyspnea; Female; Hea | 2013 |
Effects of chronic administration of β-blockers on airway responsiveness in a murine model of heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Bro | 2014 |
β2 adrenergic receptor activation governs cardiac repolarization and arrhythmogenesis in a guinea pig model of heart failure.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Amrinone; Animals; Arrhythmias, Ca | 2015 |
Impact of chronic systolic heart failure on lung structure-function relationships in large airways.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Albuterol; Case-Control Studi | 2016 |
Effect of β
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Albuterol; Case-Control Studi | 2017 |
Analysis of short-term reproducibility of arterial vasoreactivity by pulse-wave analysis after pharmacological challenge.
Topics: Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Albuterol; Endothelium, Vascular; Female; | 2009 |
Effects of clenbuterol on contractility and Ca2+ homeostasis of isolated rat ventricular myocytes.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Animals; Calcium Channels, L-Type; | 2008 |
Crosstalk of beta-adrenergic receptor subtypes through Gi blunts beta-adrenergic stimulation of L-type Ca2+ channels in canine heart failure.
Topics: Albuterol; Animals; Calcium Channels, L-Type; Dogs; GTP-Binding Protein alpha Subunits, Gi-Go; Heart | 2005 |
A pointed clue.
Topics: Acute Kidney Injury; Adult; Albuterol; Bicarbonates; Bundle-Branch Block; Calcium Gluconate; Cation | 2005 |
Cardiac dilatation and pump dysfunction without intrinsic myocardial systolic failure following chronic beta-adrenoreceptor activation.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; | 2007 |
[Highlights 2007 in hospital-based internal medicine: the point of view from the chief residents].
Topics: Accidental Falls; Aged; Albuterol; Anemia; Anticoagulants; Antidiuretic Hormone Receptor Antagonists | 2008 |
A case report of maternal death associated with betamimetics and betamethasone administration in premature labor.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Betamethasone; Female; Heart Failure; Humans; Hyaline Me | 1980 |
Clinical studies with beta 2 adrenoceptor agonists in heart failure.
Topics: Adrenergic beta-Agonists; Albuterol; Aminopyridines; Amrinone; Cardiotonic Agents; Ethanolamines; He | 1982 |
[Alternatives to digitalis therapy?].
Topics: Albuterol; Captopril; Dobutamine; Dopamine; Heart Failure; Humans; Hydralazine; Nitrates; Prazosin; | 1981 |
Salbutamol in treatment of heart failure.
Topics: Administration, Oral; Adult; Aged; Albuterol; Animals; Chronic Disease; Dose-Response Relationship, | 1980 |
Haemodynamic effects of oral salbutamol alone and in combination with sublingual isosorbide dinitrate in patients with severe congestive cardiac failure.
Topics: Aged; Albuterol; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Isosorbide | 1980 |
Synergistic effects of a combined salbutamol-nitroprusside regimen in acute myocardial infarction and severe left ventricular failure.
Topics: Aged; Albuterol; Blood Pressure; Cardiac Output; Drug Synergism; Drug Therapy, Combination; Female; | 1980 |
Acute congestive cardiac failure in a hypertensive woman receiving salbutamol for premature labour.
Topics: Adult; Albuterol; Drug Therapy, Combination; Female; Heart Failure; Humans; Hypertension; Methyldopa | 1980 |
Cardiac failure in a hypertensive woman receiving salbutamol for premature labour.
Topics: Albuterol; Female; Heart Failure; Humans; Hypertension; Obstetric Labor, Premature; Pregnancy; Pregn | 1980 |
[Myocardial postpartum hypokinesia: role of salbutamol].
Topics: Adult; Albuterol; Cardiomegaly; Chorioamnionitis; Female; Fertilization in Vitro; Heart Failure; Hum | 1993 |
Response of large and small vessels to alpha and beta adrenoceptor stimulation in heart failure: effect of angiotensin converting enzyme inhibition.
Topics: Acetylcholine; Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Albuterol; Angiotensin-Convertin | 1997 |
Can oral beta2 agonists cause heart failure?
Topics: Administration, Oral; Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Bronchodilator Agents; Coho | 1998 |
Beta2 agonists and heart failure.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Evidence-Based Medicine; H | 1998 |
Reversal of severe pulmonary hypertension with beta blockade in a patient with end stage left ventricular failure.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Cardiac Output; Dobutamine; Drug A | 1998 |
Can pre-treatment with beta-agonists reduce stress test time and the use of atropine in dobutamine stress testing?
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Albuterol; Atropine; Coronary Disease; D | 2001 |
Clinical significance of changes in beta-adrenoreceptors in peripheral lymphocytes in patients with essential hypertension.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Binding, Competitive; Blood Pressure; Dose-Respons | 2000 |
[Possibilities of respiratory rehabilitation in the hospital].
Topics: Albuterol; Anti-Bacterial Agents; Bronchodilator Agents; Diuretics; Heart Failure; Humans; Intensive | 1979 |
Haemodynamic effects of salbutamol in patients with acute myocardial infarction and severe left ventricular dysfunction.
Topics: Adult; Aged; Albuterol; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Myocardial Infarctio | 1979 |
Beneficial effect of salbutamol on cardiac function in severe congestive cardiomyopathy. Effect on systolic and diastolic function of the left ventricle.
Topics: Adult; Aged; Albuterol; Blood Pressure; Heart Failure; Heart Ventricles; Hemodynamics; Humans; Middl | 1978 |
Effects of dobutamine and salbutamol on haemodynamics and atrial natriuretic factor in patients with severe congestive heart failure.
Topics: Adult; Aged; Albuterol; Atrial Natriuretic Factor; Blood Pressure; Cardiac Output; Dobutamine; Femal | 1991 |
Bronchial hyperresponsiveness to methacholine in patients with impaired left ventricular function.
Topics: Adult; Aged; Albuterol; Bronchi; Bronchial Provocation Tests; Cardiomyopathy, Dilated; Coronary Dise | 1989 |
Cardiac failure associated with the use of salbutamol for inhibition of premature labour.
Topics: Adult; Albuterol; Female; Heart Failure; Humans; Obstetric Labor, Premature; Pregnancy | 1987 |
Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure.
Topics: Aged; Albuterol; Arrhythmias, Cardiac; Blood Pressure; Cardiac Output; Electrocardiography; Female; | 1985 |